FindTrial
Sign In

Autologous MUC1-activated T-cells

BIOLOGICAL2 trials

Sponsors

Mayo Clinic

Conditions

Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Fallopian Tube CarcinosarcomaRecurrent Female Reproductive System CarcinomaRecurrent Ovarian CarcinomaRecurrent Ovarian Carcinosarcoma

Phase 1

Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma
Active, not recruitingNCT05411497
Mayo ClinicRecurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Start: 2022-06-20End: 2027-08-18Updated: 2026-04-03
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
RecruitingNCT06483048
Mayo ClinicPlatinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma +13
Start: 2024-09-20End: 2028-09-30Target: 12Updated: 2026-03-16

Related Papers

Clinical evaluation of ex vivo expanded MUC1-specific peripheral blood T Cells for adoptive immunotherapy in relapsed/refractory multiple myeloma.
2026-06-11